To report the effect of BG-12 (dimethyl fumarate) in reducing the number of relapses requiring intravenous (IV) steroids and multiple sclerosis (MS)-related hospitalizations from a pre-specified integrated analysis of DEFINE and CONFIRM, which was designed to estimate-more precisely-the therapeutic effect of BG-12 versus placebo. METHODS: Eligible patients were aged 18-55 years with relapsing-remitting MS (McDonald criteria) and an Expanded Disability Status Scale score of 0-5.0. Patients who received oral BG-12 240 mg twice (BID) or three times daily (TID) or placebo were included and the integrated analysis was to be conducted only if baseline characteristics and treatment effects were similar between the studies. Numbers of relapses requiring IV steroids and MS-related hospitalizations (tertiary endpoints in DEFINE and CONFIRM) were assessed. RESULTS: The integrated analysis included 769, 761, and 771 patients who received BG-12 BID, TID, and placebo, respectively. Baseline characteristics and treatment effects were generally similar between DEFINE and CONFIRM. There were significantly fewer relapses requiring steroids and MS-related hospitalizations in both BG-12 groups compared with placebo. BG-12 reduced the annualized rate of relapses requiring IV steroids by 48% (BID; rate ratio, 0. OBJECTIVES: Perampanel (PER) is the first orally active α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist approved for the adjunctive treatment of partial-onset seizures in patients with epilepsy aged 12 years and older. While the regulatory approval was on the basis of 3 RCTs, which demonstrated the efficacy and acceptable safety of perampanel relative to placebo, for the purpose of funding and health technology assessment decisions comparisons to other similar AED are necessary.The aim is to compare the clinical efficacy and tolerability of PER relative to other recently approved AEDs (lacosamide (LCM), retigabine (RTG), and eslicarbazepine (ESL)) for the adjunctive treatment of partial onset seizures with or without secondarily generalization. METHODS: A systematic literature review was conducted to identify all RCTs of PER and selected AEDs. EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials from 1998 to September 2011, abstracts from selected 2010 and 2011 conferences, reference lists of included studies and unpublished study reports were searched. The odds-ratio for three outcomes: ">50% reduction in seizure frequency", "seizure freedom" and "withdrawal due to adverse events" were estimated using fixed-and random-effects Bayesian NMA models. RESULTS: Twelve RCTs (3 PER, 3 LCM, 3 RTG and 3 ESL) met the inclusion criteria. In the analysis for ">50% reduction in seizure frequency", all AEDs performed significantly better than placebo with odds-ratio for PER being similar to the other comparators. In the analysis for "seizure freedom", all AEDs except LCM performed significantly better than placebo. In the analysis for "withdrawal due to adverse events" PER had the lowest odds-ratio compared to other AEDs. No significant difference was observed in any of the three outcomes between PER and the other AEDs when compared against each other. CONCLUSIONS: Compared with other licensed adjunctive AEDs, perampanel offers similar clinical efficacy and tolerability profile. 
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PND13 CLINICAL AND NEURORADIOLOGICAL EFFECT OF BG-12 (DIMETHYL FUMARATE) IN SUBGROUPS OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): AN INTEGRATED ANALYSIS OF THE PHASE 3 DEFINE AND CONFIRM STUDIES

OBJECTIVES:
To report efficacy of BG-12 (dimethyl fumarate) in pre-specified patient subgroups stratified by age, gender, treatment history, prior relapses, Expanded Disability Status Score (EDSS), McDonald criteria, T2 lesion volume, and presence/absence of gadolinium-enhancing lesions at baseline in a prespecified integrated analysis of DEFINE and CONFIRM. This analysis was designed to estimate-more precisely-the treatment effect of BG-12 versus placebo. METHODS: Eligible patients were aged 18-55 years with a diagnosis of relapsing-remitting multiple sclerosis (RRMS) (McDonald criteria) and an EDSS score of 0-5.0. Patients receiving BG-12 240 mg twice (BID) or three times daily (TID) or placebo were included in this analysis. Primary endpoints were proportion of patients relapsed (DEFINE) and annualized relapse rate (ARR) (CONFIRM) at 2 years. Secondary endpoints included number of new/enlarging T2 lesions and disability progression. The pre-specified integrated analysis was to be conducted only if baseline characteristics and treatment effects were consistent between the studies. RESULTS: The integrated intent-to-treat population comprised 2,301 patients while MRI evaluations were performed in a cohort of 1,046 patients. Baseline characteristics and treatment effects were generally similar across studies. Both BG-12 BID and TID reduced ARR versus placebo at 2 years by approximately 50%, risk of relapse, number of new/enlarging T2 lesions, and risk of disability progression at 2 years versus placebo across the subgroups. For example, ARR versus placebo at 2 years was reduced by 50% (BID; rate ratio 0. 
PND14 PROPENSITY SCORE ANALYSIS IN MEPS 2003-2010: PCS AND MCS SCORES AFTER MIGRAINE TREATMENTS
Wu IH, Johnson ML, Aparasu RR University of Houston, Houston, TX, USA OBJECTIVES: Migraine is a public health problem that has an impact on both the individual sufferer and on society. The objective of this study was to examine the PCS (physical component summary) and MCS (mental component summary) score after being treated with one of the two different recommended level A medications -Triptans and Anti-epileptics. METHODS: MEPS data 2003-2010 (with panel 9-14) were downloaded from the AHRQ website. Migraine patients who started to receive either Triptans or Anti-epileptics in round 3 were retained in the cohort. Patients who received combination therapy or received the medication in round 1 or 2 were excluded in order to control for the baseline characteristics. Propensity score method was used to ensure the patients being compared are equal within each tertile. The predicted probability of receiving Triptans was calculated for all patients in the cohort by using multiple logistic regression to control for demographics, comorbidity and PCS/MCS in round 2. The probabilities were then stratified into tertiles. The outcomes -PCS and MCS in round 4 were compared within each tertile to examine if there were any differences between the two medications. RESULTS: Overall there were 120 patients in the cohort with weighted frequency of 2,779,074 (2,049,642 for Triptans and 729,432 for Anti-epileptics). After the propensity score stratification, all the baseline information between the two treatment cohorts were equal in each tertile except race in tertile 2 (p=0.0124). After the outcomes comparison, there were no differences in round 4 PCS and MCS score between the two medications for all three tertiles. CONCLUSIONS: Triptans are the most expensive among all the migraine medications. However, the findings of our study demonstrated there were no differences in PCS and MCS after the treatment. Future studies should examine different outcomes and see if Triptans can improve other clinical findings. 
PND15 MULTIPLE SCLEROSIS EARLY TREATMENT RATES IN UNITED STATES VETERANS
OBJECTIVES:
Multiple sclerosis (MS) is a common autoimmune demyelinating disease of the central nervous system. Early treatment of MS aids in repressing the most severe stage of acute axonal injury. The objective of this study was to characterize the proportion of MS patients who received early treatment, defined as an immunosuppressive treatment within 12 months following diagnosis. METHODS: We identified patients with an MS diagnosis who sought care in the US Veterans Health Administration (VHA) system from 1999-2010. The index date was the date of firs MS diagnosis. Patients who did not have at least 12 months of follow-up time were excluded. Descriptive statistics were used to characterize prescriptions for medications commonly used to treat MS in the 12 months following the index date. RESULTS: Our analysis cohort consisted of 6,011 MS patients. Mean age was 53.8 (SD 13.4) years and 80.7% were male. Race was known in 40.8%; of which most were white (80.2%) or black (16.0%). Only 35.3% of MS patients had a prescription for MS treatment in the 12 months following the index date. The most common MS treatments among MS patients were interferon beta 1a (13.2%), glatiramer (10.3%), amantadine (6.9%), prednisone (6.5%), and methylprednisolone (5.5%). Younger patients were more likely to have prescriptions. In a subset of 3,312 patients age <55, e.g., those who would be eligible for a clinical trial, 44.1% had a prescription for any immunosuppressive therapy used to treat MS. Interferon beta 1a (17.9%) was the most common treatment in this subgroup followed by glatiramer (13.6%), amantadine (8.9%), methylprednisolone (7.3%), and prednisone (6.8%). CONCLUSIONS: This descriptive analysis indicates that most patients with a diagnosis of MS do not receive early immunosuppressive therapy. Future research should identify relevant barriers to treatment and potential solutions to overcoming these barriers.
PND16 ANTIEPILEPTIC DRUG SWITCHING AND THE RISK OF SEIZURE-RELATED EVENTS
